MeSH D014009 - onychomycosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ciclopirox | Ciclopirox | 2007-09-18 | |||
| Efinaconazole | Efinaconazole | 2020-12-16 | ||||
| Padagis | Ciclopirox | Ciclopirox | 2006-03-03 | |||
| Efinaconazole | Efinaconazole | 2020-12-16 | ||||
| Tavaborole | Tavaborole | 2020-10-13 | ||||
| Taro Pharmaceutical | Ciclopirox | Ciclopirox | 2005-04-12 | |||
| Tavaborole | Tavaborole | 2021-05-07 | ||||
| Terbinafine | Terbinafine | 2007-07-02 | ||||
| Glenmark Pharmaceuticals | Ciclopirox | Ciclopirox | 2009-11-10 | |||
| Terbinafine | Terbinafine | 2007-07-02 | ||||
| Mylan | Ciclopirox | Ciclopirox | 2007-09-18 | |||
| Itraconazole | Itraconazole | 2012-07-20 | ||||
| Terbinafine | Terbinafine | 2007-07-02 | ||||
| NATCO Pharma | Terbinafine | Terbinafine | 2007-07-02 | |||
| Mayne Group | Itraconazole | Tolsura | 2023-07-25 | 2018-12-11 | ||
| Johnson & Johnson | Itraconazole | Sporanox | 1992-09-11 | |||
| GSK | Terbinafine | Lamisil | 1997-10-17 | |||
| Terbinafine | Lamisil At | 2000-03-17 | ||||
| Cipla | Tavaborole | Tavaborole | 2021-02-09 | |||
| Terbinafine | Terbinafine | 2007-07-02 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
50%3/6
Phase 2
55%6/11
Phase 3
92%11/12
Approved: 5Overall Success rate: 25%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use